Strategic Acquisition PreOmics is now part of Biognosys Group as of 2025, presenting a unified multiomics platform with potential cross-sell opportunities for integrated proteomics, metabolomics, and lipidomics solutions to existing Biognosys customers.

High Growth Potential Revenue is in the low to mid single digits with recent financing and a strong Bruker affiliation, suggesting capacity for sales expansion through channel partnerships, funded R&D, and scaled pilot programs with labs adopting mass spectrometry workflows.

Automation Advantage Product portfolio includes automation and sample preparation tools (BeatBox, PreON) that can reduce lab workflow time and increase throughput, presenting upsell opportunities to labs seeking end-to-end automation integrated with mass spectrometry.

Workflow Enrichment Recent kit launches such as ENRICH-iST and FFPE workflows indicate a focus on increasing proteomic depth and sample versatility, offering sales angles to expand customers’ assay sensitivity and coverage.

Platform Compatibility Vendor-neutral strategy and compatibility across major MS platforms align with organizations seeking flexible, scalable solutions; target large labs and CROs that require interoperable consumables, software, and services from a single ecosystem.